Table 1. Ongoing dedicated, recently updated clinical trials for the systemic treatment of metastatic UM.
| Agent | Phase, setting | ID number |
|---|---|---|
| Fotemustine | III, Adjuvant | EudraCT 2008-005691-27 |
| Anti-GPNMB-drug conjugate Glembatumumab Vedotin | II | NCT02363283 |
| MET inhibitor Crizotinib | II, Adjuvant | NCT02223819 |
| PDGFR,VEGFR inhibitor Sunitinib or ‘HDAC inhibitor' Valproic Acid | II, Adjuvant | NCT02068586 |
| BRAF inhibitor Sorafenib | Chemonaive | NCT01377025 |
| PKC inhibitor Sotrasturin | I | NCT01430416 |
| MEK inhibitor Selumetinib | II | NCT01143402 |
| HSP90 inhibitor Ganetespib | II | NCT01200238 |
| HDAC inhibitor Vorinostat | II | NCT01587352 |
| PKC inhibitor Sotrasturin+PI3K inhibitor Alpelisib | I | NCT02273219 |
| PKC inhibitor Sotrasturin+MEK inhibitor Binimetinib | I/II | NCT01801358 |
| MEK inhibitor Trametinib±AKT inhibitor Uprosertib | II | NCT01979523 |
| mTOR inhibitor Everolimus+Somatostatin analogue Pasireotide | II | NCT01252251 |
| MEK inhibitor SelumetinibHyd Sulfate+Dacarbazine | III | NCT01974752 |
| MEK inhibitor Selumetinib+Paclitaxel | Pending | |
| Anti-VEGF Bevacizumab+Temozolomide | II | NCT01217398 |
| BRAF inhibitor Sorafenib+Liver Radioembolisation | I | NCT01893099 |
| Dendritic cells vaccination | I/II, Adjuvant | NCT00929019 |
| Dendritic cells vaccination | III, Adjuvant | NCT01983748 |
| Anti-PD1 Pembrolizumab | II | NCT02359851 |
| Tumour-infiltrating lymphocytes | II | NCT01814046 |
| Anti-CTLA4 Ipilimumab+anti-PD1 Nivolumab | II | NCT01585194 |
| Anti-CTLA4 Ipilimumab+Liver Radioembolisation | I | NCT01730157 |
Abbreviations: HDAC=histone deacetylase; mTOR=mammaliam target of rapamycin; PDGFR=platelet-derived growth factor receptor; PI3K=phosphoinositide 3-kinase; PKC=protein kinase C; UM=uveal melanoma; VEGFR=vascular endothelial growth factor receptor.